COSCIENS Biopharma Inc. filings document a foreign private issuer reporting on Form 6-K and related U.S. disclosure obligations for its common shares. The company’s regulatory record includes material-event reports, notices for annual and special shareholder meetings, management proxy circular materials, and disclosures tied to capital-structure and shareholder voting matters.
Filings also cover governance, risk factors, operating and financial results, material agreements, and clinical or regulatory disclosures connected to COSCIENS’ life science business, including natural active ingredients and diagnostic-product activities. The records frame corporate-status matters such as Nasdaq delisting and U.S. reporting obligations through formal securities-law documents.
COSCIENS Biopharma Inc. has scheduled its annual general and special meeting of shareholders as a virtual meeting on June 17, 2026. The company set May 18, 2026 as the record date for notice, voting, and beneficial ownership determination, meaning only holders of common shares on that date are entitled to receive materials and vote. The filing also notes that proxy-related materials will not be sent directly to non-objecting beneficial owners, and the issuer will pay for delivery to objecting beneficial owners.
COSCIENS Biopharma Inc. has scheduled its annual general and special meeting of shareholders as a virtual meeting on June 17, 2026. The company set May 18, 2026 as the record date for notice, voting, and beneficial ownership determination, meaning only holders of common shares on that date are entitled to receive materials and vote. The filing also notes that proxy-related materials will not be sent directly to non-objecting beneficial owners, and the issuer will pay for delivery to objecting beneficial owners.
COSCIENS Biopharma Inc. is asking shareholders to approve a complex share capital change that will effectively cash out many small positions and allow the company to stop filing reports with the U.S. SEC. The plan combines a 1‑for‑150 consolidation with a 50‑for‑1 split. Holders with fewer than 150 shares in any registered position will be bought out for U.S.$1.60 per pre‑consolidation share, while others keep their stake and see their share count unchanged after the split. COSCIENS expects this to cut U.S. holders of record below 300, enabling a Form 15 filing and an estimated ~U.S.$1.9 million in annual cost savings, while its stock remains listed on the TSX and quoted on the OTCQB.
COSCIENS Biopharma Inc. is asking shareholders to approve a complex share capital change that will effectively cash out many small positions and allow the company to stop filing reports with the U.S. SEC. The plan combines a 1‑for‑150 consolidation with a 50‑for‑1 split. Holders with fewer than 150 shares in any registered position will be bought out for U.S.$1.60 per pre‑consolidation share, while others keep their stake and see their share count unchanged after the split. COSCIENS expects this to cut U.S. holders of record below 300, enabling a Form 15 filing and an estimated ~U.S.$1.9 million in annual cost savings, while its stock remains listed on the TSX and quoted on the OTCQB.
PETER PUCCETTI AND PUCCETTI FUNDS MANAGEMENT INC. have sharply reduced their reported stake in COSCIENS Biopharma Inc. to 15,687 common shares, representing about 0.5% of shares outstanding. This follows the sale of all of Puccetti’s indirect equity interest in Goodwood Inc., which managed Goodwood Fund.
Goodwood Fund previously held 241,570 COSCIENS shares that had been reported as beneficially owned by the reporting persons. After the transaction, Puccetti no longer owns or controls Goodwood, Goodwood Fund, or those shares, and a prior joint filing agreement among the parties has been terminated.
The filing confirms Puccetti’s remaining exposure is held indirectly through Puccetti Funds and that the group has ceased to beneficially own more than 5% of COSCIENS common stock, though Puccetti continues to serve as interim CEO and chair of the board.
PETER PUCCETTI AND PUCCETTI FUNDS MANAGEMENT INC. have sharply reduced their reported stake in COSCIENS Biopharma Inc. to 15,687 common shares, representing about 0.5% of shares outstanding. This follows the sale of all of Puccetti’s indirect equity interest in Goodwood Inc., which managed Goodwood Fund.
Goodwood Fund previously held 241,570 COSCIENS shares that had been reported as beneficially owned by the reporting persons. After the transaction, Puccetti no longer owns or controls Goodwood, Goodwood Fund, or those shares, and a prior joint filing agreement among the parties has been terminated.
The filing confirms Puccetti’s remaining exposure is held indirectly through Puccetti Funds and that the group has ceased to beneficially own more than 5% of COSCIENS common stock, though Puccetti continues to serve as interim CEO and chair of the board.
COSCIENS Biopharma Inc. filed a report to share a press release responding to unusual trading in its shares. The company states it is not aware of any material undisclosed information that would explain the recent increase in trading volume and price of its common stock.
The filing also repeats extensive forward-looking statement cautions, highlighting risks tied to potential insolvency proceedings of its German subsidiaries, development and commercialization of its patented natural active ingredients, liquidity and capital resources, and internal controls. COSCIENS describes itself as a life science company focused on plant-based ingredients used in skincare products.
COSCIENS Biopharma Inc. filed a report to share a press release responding to unusual trading in its shares. The company states it is not aware of any material undisclosed information that would explain the recent increase in trading volume and price of its common stock.
The filing also repeats extensive forward-looking statement cautions, highlighting risks tied to potential insolvency proceedings of its German subsidiaries, development and commercialization of its patented natural active ingredients, liquidity and capital resources, and internal controls. COSCIENS describes itself as a life science company focused on plant-based ingredients used in skincare products.
COSCIENS Biopharma Inc., a Canada-based company listed on the TSX and OTCQB, files its annual Form 20-F for the year ended December 31, 2025. The company had 3,183,330 Common Shares outstanding as of December 31, 2025.
COSCIENS focuses on oat-based cosmeceutical and nutraceutical ingredients (including oat beta-glucan and avenanthramides) and on commercializing its licensed PGX Technology for processing biopolymers into high-value materials. A large majority of current revenue comes from a single distribution partner, Symrise AG, under an exclusive supply and distribution agreement that runs to December 31, 2026.
The filing highlights substantial risk, including a disclosed substantial doubt about the company’s ability to continue as a going concern, heavy reliance on Symrise AG for over 84% of revenues, significant financing needs, and exposure to tariffs, raw-material supply disruptions and intense competition. COSCIENS is also managing insolvency proceedings for its German subsidiaries, which may lead to surrendering rights to Macrilen and potential non-cash accounting impacts. Additional risks include possible PFIC tax status for U.S. holders, volatility in its share price, potential TSX delisting, cybersecurity threats, environmental obligations, and prior material weaknesses in internal controls that the company reports as remediated in 2025.
COSCIENS Biopharma Inc., a Canada-based company listed on the TSX and OTCQB, files its annual Form 20-F for the year ended December 31, 2025. The company had 3,183,330 Common Shares outstanding as of December 31, 2025.
COSCIENS focuses on oat-based cosmeceutical and nutraceutical ingredients (including oat beta-glucan and avenanthramides) and on commercializing its licensed PGX Technology for processing biopolymers into high-value materials. A large majority of current revenue comes from a single distribution partner, Symrise AG, under an exclusive supply and distribution agreement that runs to December 31, 2026.
The filing highlights substantial risk, including a disclosed substantial doubt about the company’s ability to continue as a going concern, heavy reliance on Symrise AG for over 84% of revenues, significant financing needs, and exposure to tariffs, raw-material supply disruptions and intense competition. COSCIENS is also managing insolvency proceedings for its German subsidiaries, which may lead to surrendering rights to Macrilen and potential non-cash accounting impacts. Additional risks include possible PFIC tax status for U.S. holders, volatility in its share price, potential TSX delisting, cybersecurity threats, environmental obligations, and prior material weaknesses in internal controls that the company reports as remediated in 2025.
COSCIENS Biopharma Inc. has decided to stop funding its German subsidiaries, Aeterna Zentaris GmbH and Zentaris IVF GmbH. The Company expects these entities to enter a structured insolvency process and to surrender its rights to Macrilen, its main FDA and EMA approved pharmaceutical asset.
Management explains that Macrilen and the broader biopharmaceutical business have operated at a loss, and a failed Phase 3 DETECT trial for a pediatric indication in the U.S. undermined growth plans. COSCIENS plans to significantly cut ongoing operating expenses and focus on its plant-based active ingredients business, including avenanthramides and beta glucan used in skincare products.
COSCIENS Biopharma Inc. has decided to stop funding its German subsidiaries, Aeterna Zentaris GmbH and Zentaris IVF GmbH. The Company expects these entities to enter a structured insolvency process and to surrender its rights to Macrilen, its main FDA and EMA approved pharmaceutical asset.
Management explains that Macrilen and the broader biopharmaceutical business have operated at a loss, and a failed Phase 3 DETECT trial for a pediatric indication in the U.S. undermined growth plans. COSCIENS plans to significantly cut ongoing operating expenses and focus on its plant-based active ingredients business, including avenanthramides and beta glucan used in skincare products.
COSCIENS Biopharma Inc. filed a report describing an upcoming special meeting of its security holders. The company, through its transfer agent Computershare, set March 3, 2026 as the record date for notice and voting, with the meeting scheduled for April 7, 2026 as a virtual event.
The filing also reiterates extensive forward-looking statement cautions, highlighting risks related to its patented technologies, nutraceutical and pharmaceutical product development, facility build-outs, liquidity and capital resources, and overall business strategy. Common shares are identified as the voting security for this special meeting.
COSCIENS Biopharma Inc. filed a report describing an upcoming special meeting of its security holders. The company, through its transfer agent Computershare, set March 3, 2026 as the record date for notice and voting, with the meeting scheduled for April 7, 2026 as a virtual event.
The filing also reiterates extensive forward-looking statement cautions, highlighting risks related to its patented technologies, nutraceutical and pharmaceutical product development, facility build-outs, liquidity and capital resources, and overall business strategy. Common shares are identified as the voting security for this special meeting.